173 related articles for article (PubMed ID: 28117675)
1. F-Box Protein FBXO22 Mediates Polyubiquitination and Degradation of CD147 to Reverse Cisplatin Resistance of Tumor Cells.
Wu B; Liu ZY; Cui J; Yang XM; Jing L; Zhou Y; Chen ZN; Jiang JL
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117675
[TBL] [Abstract][Full Text] [Related]
2. F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression.
Tian X; Dai S; Sun J; Jin G; Jiang S; Meng F; Li Y; Wu D; Jiang Y
Oncotarget; 2015 Sep; 6(26):22767-75. PubMed ID: 26087183
[TBL] [Abstract][Full Text] [Related]
3. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
[TBL] [Abstract][Full Text] [Related]
4. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
5. FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
Johmura Y; Harris AS; Ohta T; Nakanishi M
Cancer Sci; 2020 Aug; 111(8):2718-2725. PubMed ID: 32536008
[TBL] [Abstract][Full Text] [Related]
6. FBXO22 protein is required for optimal synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine.
Dikopoltsev E; Foltyn VN; Zehl M; Jensen ON; Mori H; Radzishevsky I; Wolosker H
J Biol Chem; 2014 Dec; 289(49):33904-15. PubMed ID: 25336657
[TBL] [Abstract][Full Text] [Related]
7. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.
Johmura Y; Sun J; Kitagawa K; Nakanishi K; Kuno T; Naiki-Ito A; Sawada Y; Miyamoto T; Okabe A; Aburatani H; Li S; Miyoshi I; Takahashi S; Kitagawa M; Nakanishi M
Nat Commun; 2016 Feb; 7():10574. PubMed ID: 26868148
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
De S; Holvey-Bates EG; Mahen K; Willard B; Stark GR
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34795058
[TBL] [Abstract][Full Text] [Related]
9. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
Tan MK; Lim HJ; Harper JW
Mol Cell Biol; 2011 Sep; 31(18):3687-99. PubMed ID: 21768309
[TBL] [Abstract][Full Text] [Related]
10. Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.
Jeon YK; Kim CK; Koh J; Chung DH; Ha GH
Oncotarget; 2016 Jul; 7(27):41811-41824. PubMed ID: 27248820
[TBL] [Abstract][Full Text] [Related]
11. FBXO22, ubiquitination degradation of PHLPP1, ameliorates rotenone induced neurotoxicity by activating AKT pathway.
Zheng X; Yu S; Xue Y; Yan F
Toxicol Lett; 2021 Oct; 350():1-9. PubMed ID: 34182063
[TBL] [Abstract][Full Text] [Related]
12. Fbxo22 promotes cervical cancer progression via targeting p57
Lin M; Zhang J; Bouamar H; Wang Z; Sun LZ; Zhu X
Cell Death Dis; 2022 Sep; 13(9):805. PubMed ID: 36127346
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells.
Huang Z; Wang L; Wang Y; Zhuo Y; Li H; Chen J; Chen W
J Oral Pathol Med; 2013 Aug; 42(7):541-6. PubMed ID: 23413783
[TBL] [Abstract][Full Text] [Related]
14. FBXO22 inhibits proliferation and metastasis of cervical cancer cells by mediating ubiquitination-dependent degradation of GAK.
Li S; Shi L; Wang Y; Zhang L; Chu S; Li M; Bai J; Zhu W
Exp Cell Res; 2023 Sep; 430(1):113719. PubMed ID: 37442264
[TBL] [Abstract][Full Text] [Related]
15. SCF
Bai J; Wu K; Cao MH; Yang Y; Pan Y; Liu H; He Y; Itahana Y; Huang L; Zheng JN; Pan ZQ
Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11754-11763. PubMed ID: 31138683
[TBL] [Abstract][Full Text] [Related]
16. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Johmura Y; Maeda I; Suzuki N; Wu W; Goda A; Morita M; Yamaguchi K; Yamamoto M; Nagasawa S; Kojima Y; Tsugawa K; Inoue N; Miyoshi Y; Osako T; Akiyama F; Maruyama R; Inoue JI; Furukawa Y; Ohta T; Nakanishi M
J Clin Invest; 2018 Dec; 128(12):5603-5619. PubMed ID: 30418174
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of CD147 expression by RNA interference inhibits HT29 cell proliferation, invasion and tumorigenicity in vitro and in vivo.
Li R; Pan Y; He B; Xu Y; Gao T; Song G; Sun H; Deng Q; Wang S
Int J Oncol; 2013 Dec; 43(6):1885-94. PubMed ID: 24064772
[TBL] [Abstract][Full Text] [Related]
18. Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells.
Wang WJ; Li QQ; Xu JD; Cao XX; Li HX; Tang F; Chen Q; Yang JM; Xu ZD; Liu XP
Chemotherapy; 2008; 54(4):291-301. PubMed ID: 18689982
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells.
Zhu C; Pan Y; He B; Wang B; Xu Y; Qu L; Bao Q; Tian F; Wang S
Oncol Rep; 2011 Feb; 25(2):425-32. PubMed ID: 21165561
[TBL] [Abstract][Full Text] [Related]
20. TCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cells.
Liu X; Wang C; Gu Y; Zhang Z; Zheng G; He Z
Mol Cell Biochem; 2015 Jan; 398(1-2):175-83. PubMed ID: 25260657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
